Stock fact sheet · data as of
Pacira BioSciences, Inc. (PCRX): fair value, margin of safety and Wheel Score
Ticker symbol PCRX · Healthcare · Drug Manufacturers - Specialty & Generic · United States · Blend
Is PCRX undervalued?
PCRX closed at 36.40 on 5 Nov 2026, 16% below the GLS average fair value of 43.35 from 8 models (2 of them above the price). That is a moderate margin of safety: the stock passes the "below fair value" Wheel Trade Filter, with room for a bigger discount on the Value part.
There is a wide gap between GLS Growth (1.09) and DCF (204.27). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.
Ranked against every other company we cover, neither cheapness nor growth clearly wins for PCRX, so the nightly engine files it under Blend (value score 46, growth score 26, out of 100).
Nine valuation models for PCRX
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 204.27 | +461% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | 11.92 | -67% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 10.24 | -72% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 3.66 | -90% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 1.09 | -97% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | 93.75 | +158% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | 17.77 | -51% | Eight years of compounded free cash flow: the price at which the business pays for itself |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 4.12 | -89% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | -0.5979 | -102% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 31.60 | -13% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Pacira BioSciences, Inc. scores 8 of 9 on the Piotroski F-score, the nine yes/no tests of profitability, leverage and efficiency on the latest annual accounts - a strong reading that passes the "Piotroski 6 or more" Wheel Trade Filter with room to spare. A GLS Moat score of 4.3/10 is a weak reading: the accounts do not show returns and margins that competitors have been unable to wear down, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC 0.6%, ROE 1.0%, ROA 0.6% - with debt at 0.66 times equity and a free-cash-flow yield of 12.4%.
Pacira BioSciences, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Product 51%, Exparel 40%, Zilretta 9% (quarter Q2 FY2026).
Institutional ownership scores 10/10, insider activity 3/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 8 / 9 | ROIC | 0.6% |
|---|---|---|---|
| GLS Moat | 4.3 / 10 | ROE | 1.0% |
| Debt / equity | 0.66 | ROA | 0.6% |
| Free-cash-flow yield | 12.4% | Payout ratio | 0% |
| Institutions | 10 / 10 | Insiders · Congress | 3 · 5 / 10 |
Wheel Score 29: Weak
With a Wheel Score of 29 Pacira BioSciences, Inc. sits in the Weak band. It fails filter 7, a premium worth selling - implied volatility 21% (under 25%); Premium (weak) is its weakest part.
Implied volatility on the near-the-money contracts is 21%, below the 25% the Wheel Trade Filter on premium asks for: a put pays too little to be worth selling. Chain open interest is 3,628 contracts across all expiries - enough for the wheel at normal size.
Volume runs at 2.4M shares a day on a market cap of $1.5B, with a beta of 0.25 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score rates that fair.
| Filter | Wheel Trade Filter | Result | Detail |
|---|---|---|---|
| 1 | Options that actually trade | Passes | Listed options with 1,000+ contracts of open interest and 100+ traded a day |
| 2 | A real business, not a gamble | Passes | Profitable over the last twelve months - not a speculative stock, fund or note |
| 3 | Below fair value | Passes | Trading below the nine-model average fair value (margin of safety above 0) |
| 4 | Financially healthy | Passes | Piotroski F-score 6 or more out of 9 (a company with no score on file passes) |
| 5 | Can repay its debt | Passes | Long-term debt repaid from 3 years of operating cash flow or less (6 for real estate and utilities; banks and insurers are not judged on it) |
| 6 | No serious red flags | Passes | Red Flags score 60 or more out of 100 (earnings, margins, debt, analysts, filings and price checked the same way for every stock) |
| 7 | A premium worth selling | Fails | implied volatility 21% (under 25%) |
| 8 | Big enough | Passes | Market cap $1 billion or more |
| 9 | Not a penny stock | Passes | Share price $5 or more |
| How it ranks | Rating | From | |
|---|---|---|---|
| Value | Fair | 16% below fair value | |
| Premium | Weak | implied volatility 21% | |
| Moat | Fair | moat 4.3/10 | |
| Health | Strong | Piotroski 8/9 | |
| Red Flags | Fair | Red Flags score 72/100 | |
| Option trading | Weak | 244 contracts a day, 3,628 open interest | |
| Stability | Fair | beta 0.25, $1.5B company |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls: a stock must pass all 9 Wheel Trade Filters to score 70, and the score then ranks the ones that pass; the Sunday Scan is the top 10. It is updated nightly and is not a recommendation. How the Wheel Score works · the walkthrough lesson shows how it fits into a trade, start to finish.
Upcoming events
Pacira BioSciences, Inc. reports earnings on 5 Nov 2026 (after the close) - inside the 14-day window the Sunday Scan avoids, because a put sold now would carry the report's gap risk.
Analysts downgraded PCRX 5 times in the last 30 days with no upgrades; the latest action was a downgrade by H.C. Wainwright on 9 Oct 2026.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Drug Manufacturers - Specialty & Generic
The 12 companies below are the closest to Pacira BioSciences, Inc. by market cap within the Drug Manufacturers - Specialty & Generic industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| ETON Eton Pharmaceuticals, Inc. | 50.72 | 15.29 | -232% | 26Weak | $1.4B |
| PAHC Phibro Animal Health Corporation | 39.43 | 47.35 | +17% | 43Weak | $1.6B |
| CRON Cronos Group Inc. | 3.51 | 2.98 | -18% | 37Weak | $1.3B |
| SUPN Supernus, Inc. | 28.21 | 87.23 | +68% | 48Weak | $1.6B |
| ANIP ANI Pharmaceuticals, Inc. | 71.65 | 251.58 | +72% | 49Weak | $1.6B |
| ALVO Alvotech | 4.67 | - | - | 14No options | $1.7B |
| AMPH Amphastar Pharmaceuticals, Inc. | 28.02 | 45.64 | +39% | 50Fair | $1.2B |
| HROW Harrow Health, Inc. | 28.75 | 4.96 | -480% | 26Weak | $1.1B |
| TRLV Trulieve Cannabis Corp. | 11.60 | 25.12 | +54% | 30Weak | $2.0B |
| PRGO Perrigo Company plc | 15.83 | 47.02 | +66% | 44Weak | $2.2B |
| HCM HUTCHMED (China) Limited | 13.92 | 2.86 | -386% | 31Weak | $2.4B |
| RGC Regencell Bioscience Holdings Limited | 5.42 | 0.0281 | -19191% | 8Weak | $2.7B |
Scan the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the top 10 stocks that pass all 9 Wheel Trade Filters, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about PCRX
Is PCRX undervalued right now?
By the GLS models, moderately: at 36.40 the stock trades 16% below the average fair value of 43.35 (data as of 5 Nov 2026).
What is the Wheel Score of PCRX and what does it mean?
PCRX scores 29 out of 100 (Weak) - it fails Wheel Trade Filter 7. The Wheel Score ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned - in two parts: the 9 pass/fail Wheel Trade Filters (busy options, a real business, below fair value, Piotroski 6 or more, debt it can repay, a Red Flags score of 60 or more, implied volatility of 25-80%, a $1 billion company, $5 a share) and a ranking of how strongly a stock passes on value, premium, moat, health, red flags, option trading and stability. A stock that fails any filter stays under 70; 70-84 is Good, 85 and above is Prime. The Sunday Scan is the top 10 that pass, sorted by Wheel Score.
What is the GLS fair value for PCRX?
43.35 per share as of 5 Nov 2026 - the simple average of the 8 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Pacira BioSciences, Inc. report earnings next?
The next earnings report is due on 5 Nov 2026 (after the close), 0 days from the data date of 5 Nov 2026. The Calendars page lists every upcoming report with its time of day.
Does PCRX have listed options, and how liquid are they?
Yes. The nightly snapshot found 72 listed contracts with 3,628 open interest across all expiries and implied volatility of 21% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.